CD19 and acute lymphoblastic leukemia: Brexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy that was approved in the USA to treat adults with R/R B-ALL based on the positive results of the ZUMA-3 study [6].